Advanced search
Publication Cover
Expert Opinion on Drug Discovery Volume 11, 2016 - Issue 11: Leukemia and Lymphoma Drug Discovery
Submit an article Journal homepage
1,265
Views
2
CrossRef citations to date
0
Altmetric
Editorial

The application of mass spectrometry to leukemia drug discovery

Gail J. RobozDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY, USACorrespondence[email protected]
View further author information
&
John RobozDepartment of Medicine, Division of Hematology/Oncology, Icahn School of Medicine of Mount Sinai, New York, NY, USAView further author information
Pages 1029-1032 | Received 30 Jun 2016, Accepted 02 Sep 2016, Published online: 23 Sep 2016

References

  • Roboz J,Roboz G. Mass spectrometry in leukemia research and treatment. Expert Rev Hematol. 2015;8:225–235. DOI:10.1586/17474086.2015.1018889.
  • Greaves J, Roboz J. Mass spectrometry for the novice. Boca Raton (FL): CRC Press; 2013.
  • Atasever-Arsian B, Yilancioglu K, Kalkan Z, et al. Screening of new antileukemic agents from essential oils of algae extracts and computational modeling of their interactions with intracellular signaling nodes. Eur J Pharm Sci. 2016;83:121–131.
  • Dolai S, Sia K, Robbins A, et al. Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia. Cancer Res. 1016;76:2766–2777. DOI:10.1158/0008-5472.CAN-15-2786.
  • Andriamanana IGI, Duretz B, Hulin A. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. J Chromatogr B. 2013;926:83–91. DOI:10.1016/j.jchromb.2013.01.037.
  • Lindblad O, Cordero E, Puissant A, et al. Aberrant activation of the Pl3KmTOR pathway promotes resitance to sorafenib in AML. Oncogene. 2016 Mar 21. DOI:10.1038/onc.2016.41.
  • Lee J, Park Y, Lee K. Hydrogen-deuterium exchange mass spectrometry for determining protein structural changes in drug discovery. Arch Pharm Res. 2015;38:1737–174. DOI:10.1007/s12272-015-0584-9.
  • Huang R, Chen G. Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends. Drug Discov Today. 2016;21:850–855. DOI:10.1016/j.drudis.2016.04.004.
  • Kapoor I, Pal P, Lochab S, et al. Proteomics approaches for myeloid leukemia drug discovery. Expert Opin Drug Discov. 2012;7:1165–1175. DOI:10.1517/17460441.2012.724055
  • Schirle M, Bantscheff M, Kuster B. Mass spectrometry-based proteomics in preclinical drug discovery. Chem Biol. 2012;19:72–84. DOI:10.1016/j.chembiol.2012.01.002.
  • Stäubert C, Bhuiyan H, Lindahl A, et al. Rewired metabolism in drug-resistant leukemia cells: a metabolic switch hallmarked by reduced dependence on exogenous glutamine. J Biol Chem. 2015;290:8348–8358. DOI:10.1074/jbc.M114.618769.
  • Zhang F, Dai X, Wang Y. 2-Aza-2ʹ-deoxycytidine induced growth inhibition of leukemia cells through modulating endogeneous cholesterol biosynthesis. Mol Cell Proteomics. 2012;11:M111.016915. DOI:10.1074/mcp.M111.016915.
  • Han L, Qiu P, Zeng Z, et al. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A. 2015;87:346–356. DOI:10.1002/cyto.a.22628.
  • Middeke J, Herbst R, Parmentier S, et al. Clofarabine salvage therapy before allogeneic hematopoetic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial. Leukemia. 2016;30:261–267. DOI:10.1038/leu.2015.226.
  • Büttner B, Oertel R, Schetelig J, et al. Simultaneous determination of clofarabine and cytarabine in human plasma by LC-MS/MS. J Pharm Biomed Anal. 2016;125:286–291. DOI:10.1016/j.jpba.2016.03.056.
  • Balss J, Thiede S, Bochtler T, et al. Pretreatment D-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia. Leukemia. 2016;30:782–788. DOI:10.1038/leu.2015.317.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.